Observational studyBMC neurology2025
Thiamine use and short-term prognosis in critical cerebrovascular disease: a propensity score matched retrospective analysis from the MIMIC-IV database.
Observational study in BMC neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of thiamine supplementation with 30-day mortality among ICU patients with sepsis-associated delirium.Scientific reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIn the realm of critical care, cerebrovascular disease remains a major factor in patient morbidity and mortality, with limited treatment options outside of acute interventions. The importance of thiamine (vitamin B1) in energy metabolism is well-known, and it may provide neuroprotective benefits, though its role in serious cerebrovascular diseases is still uncertain.
methodsUsing data from the MIMIC-IV database, this retrospective cohort study explored the relationship between thiamine and short-term outcomes in patients with critical cerebrovascular conditions. The application of propensity score matching (PSM) helped to balance covariates between users and non-users of thiamine. The study's primary and secondary endpoints were the all-cause mortality at 7, 14, and 28 days. To estimate hazard ratios (HR) and 95% confidence interval (CI), Cox proportional hazards models were used, along with analyses for subgroups, dose-response, and duration-response.
resultsAmong 11,814 patients, 1,647 received thiamine. With 1,585 matched pairs post-PSM, thiamine administration showed a significant association with decreased mortality at 7 days (HR = 0.68, 95%CI: 0.53-0.89, P = 0.004), 14 days (HR = 0.78, 95%CI: 0.64-0.96, P = 0.016), and 28 days (HR = 0.82, 95%CI: 0.69-0.98, P = 0.028) compared with non-thiamine use after adjustment. Subgroup analyses revealed stronger benefits in patients aged ≥ 65 years, females, and those without mannitol or thrombolysis. Enhanced outcomes were most consistently observed with treatment durations longer than 5 days and daily doses lower than 100 mg.
conclusionsThiamine supplementation correlated with a reduction in short-term mortality for patients with critical cerebrovascular conditions, especially with prolonged treatment and reduced daily doses. While these observations propose thiamine as a possible supportive metabolic therapy, the evidence remains insufficient to guide clinical practice and should be considered hypothesis-generating pending confirmation in randomized trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.